Arresto Biosciences, Inc. was a privately-held, development-stage biotechnology company headquartered in Palo Alto, California, focused on medicines to treat fibrotic diseases and cancer by targeting enzymes involved in the synthesis of the extracellular matrix. Its lead product was AB0024, a humanized monoclonal antibody targeting the human lysyl oxidase-like-2 (LOXL2) protein, then in Phase I studies for idiopathic pulmonary fibrosis and advanced solid tumors. Founded circa 2007 and backed by Kleiner Perkins Caufield & Byers, HealthCare Ventures, Northgate Capital, DAG Ventures and Abbott Biotech Ventures, Arresto was acquired by Gilead Sciences for $225 million; the deal was announced December 20, 2010 and had closed by February 2011. The company no longer operates as an independent entity, publishes no developer or API surface, and its former domain (arrestobio.com) no longer resolves.
Arresto Biosciences is profiled on the APIs.io network. Tagged areas include Company, Healthcare, Biotechnology, Biopharmaceutical, and Life Sciences.
aid: arresto-biosciences
deliveryModel:
model: unknown
open_source: false
commercial: false
callable_host: false
label: Delivery model not determined — needs a product licence on record
confidence: low
source:
- none
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source: []
generated: '2026-07-22'
method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/arresto-biosciences.png
name: Arresto Biosciences
description: Arresto Biosciences, Inc. was a privately-held, development-stage biotechnology company headquartered in Palo
Alto, California, focused on medicines to treat fibrotic diseases and cancer by targeting enzymes involved in the synthesis
of the extracellular matrix. Its lead product was AB0024, a humanized monoclonal antibody targeting the human lysyl oxidase-like-2
(LOXL2) protein, then in Phase I studies for idiopathic pulmonary fibrosis and advanced solid tumors. Founded circa 2007
and backed by Kleiner Perkins Caufield & Byers, HealthCare Ventures, Northgate Capital, DAG Ventures and Abbott Biotech
Ventures, Arresto was acquired by Gilead Sciences for $225 million; the deal was announced December 20, 2010 and had closed
by February 2011. The company no longer operates as an independent entity, publishes no developer or API surface, and its
former domain (arrestobio.com) no longer resolves.
url: https://raw.githubusercontent.com/api-evangelist/arresto-biosciences/refs/heads/main/apis.yml
x-api-posture: no-product-api
x-api-posture-basis: observed
x-type: company
x-source: vc-portfolio
x-backed-by:
- kleiner-perkins
x-status: acquired
x-status-detail: 'Acquired by Gilead Sciences (Nasdaq: GILD) for $225 million; announced 2010-12-20, closed Q1 2011. No longer
an independent operating company.'
x-acquisition:
acquirer: Gilead Sciences, Inc.
acquirer_slug: gilead-sciences
amount_usd: 225000000
announced: '2010-12-20'
closed_by: '2011-02-21'
source: https://www.sec.gov/Archives/edgar/data/882095/000129993310004530/exhibit1.htm
x-former-website: http://www.arrestobio.com
x-investors:
- Kleiner Perkins Caufield & Byers
- HealthCare Ventures
- Northgate Capital
- DAG Ventures
- Abbott Biotech Ventures
x-headquarters: Palo Alto, California, United States
x-lead-asset: AB0024, humanized monoclonal antibody targeting LOXL2
x-api-surface: none
x-api-surface-reason: Defunct pre-clinical biotechnology company; never published a public API, developer portal, or documentation.
Former domain does not resolve (no A/NS records, 2026-07-19).
x-tier: stub
x-tier-reason: defunct-acquired-no-api-surface
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Healthcare
- Biotechnology
- Biopharmaceutical
- Life Sciences
- Drug Discovery
- Oncology
- Fibrosis
- Monoclonal Antibodies
- Acquired
apis: []
common:
- type: ParentCompany
url: https://apis.io/providers/gilead-sciences/
name: Gilead Sciences
x-relationship: acquired
x-evidence: Founded circa 2007 and backed by Kleiner Perkins Caufield & Byers, HealthCare Ventures, Northgate Capital, DAG
Ventures and Abbott Biotech Ventures, Arresto was acquired by Gilead Sciences for $225 million; the deal was announced
December 2
- type: LLMsTxt
url: llms/arresto-biosciences-llms.txt
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
x-enrichment:
date: '2026-07-19'
status: minimal
artifacts_added: 1
pass: local-v1
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.